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Introduction
Cyclophosphamide (CP), a cytotoxic alkylating 
agent, is extensively used as an antineoplastic 
agent for the treatment of various cancers and as an 
 immunosuppressive agent for organ transplantation, 
systemic lupus erythematosus, as well as for some 
other benign diseases (Selvakumar et al., 2006). 
CP is a prodrug that requires in vivo  metabolism 
to form the reactive component, acrolein, and 
phosphoramide mustard (Anderson et al., 1995). 
These toxic metabolites have been shown to reduce 
lung microsomal enzyme activity and decrease the 
proper  function of the antioxidant defense system 
in mammals (Kumari and Shaoo, 2005). Long-term 
CP treatment causes adverse effects, such as marked 
myelosuppression (Shah et al., 2008), which is a 
major potential toxic and dose-limiting side effect of 
CP. CP causes cross-linking of DNA and inhibits DNA 
synthesis by acting on both cyclic and  intermitotic 
cells, resulting in a general depletion of immune 
component cells (George et al., 2008). In addition 
to carcinogenic and teratogenic potentials, CP has 
also well-known toxic effects on heart, bladder, and 
hematopoietic system and causes leucopenia and a 
reduction in platelet number (Langford, 1997).
Numerous studies have shown that CP exposure 
enhances intracellular reactive oxygen species 
(ROS) production, suggesting that biochemical 
and physiological disturbances may result from 
oxidative stress (Manda and Bhatia, 2003). Studies 
in mammals suggest that CP causes acute damage 
to the blood-forming tissues in the bone marrow, 
thereby causing transient reduction in circulating 
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Abstract
Cyclophosphamide (CP) is a widely used antineoplastic drug that causes toxicity in the normal cell due to 
its metabolites. The major drawback of this drug is an undesirable myelosuppression. Selenium (Se) is a 
potent nutritional antioxidant that carries out biological effects by its incorporation into selenoproteins, 
such as glutathione peroxidase (GPx). The possible protective effects of seleno-L-methionine (SLM) against 
CP-related toxicity of blood cells and bone marrow of rats were investigated in this study. Intraperitoneal 
(i.p) administration of 50, 100, or 150 mg/kg of CP caused, in a dose-dependent manner, reductions in the 
number of leukocytes (78, 89, and 92%, respectively), thrombocytes (22, 33, and 52%, respectively), and 
bone marrow–nucleated cells (72, 90, and 94%, respectively). The groups that had CP treatment alone were 
killed 3 days after the CP injection. For the groups having CP+SLM, SLM (0.4 or 0.8 mg/kg i.p) administra-
tion was started 3 days earlier than the CP administration and continued to the end of the experiment  
(6 days). On day 4, the animals were weighed again, relative doses of CP were estimated, and CP+SLM was 
 administered together. On day 7, blood samples were collected and bone marrow of animals were resected 
under anesthesia. The results indicated that treatment of rats within a select dose range of SLM could 
reduce CP-induced toxicity on blood cells and bone marrow.
Keywords: Cyclophosphamide; seleno-L-methionine; hematoxicity; cytoprotectivity; rats
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PMNs (polymorphonuclear neutrophils), thus 
affecting the innate immune system. CP also 
causes a reduction in microsomal enzyme activity 
and reductions in the antioxidant defense system 
and also reduces specific immunity through direct 
depletion of  lymphoid tissues, thus preventing the 
host from raising an adequate specific immune 
response (Kumari and Shaoo, 2005).
The combination of the drug together with a 
potent antioxidant may be the appropriate approach 
to reduce the side effects of CP (Selvakumar et al., 
2006). Thus, in a study when CP was administrated 
with ZnCl
2
, there was a significant protection against 
CP-induced hematoxicity and urotoxicity observed 
in animals pretreated with ZnCl
2
 (Ayhanci et al., 
2009). Antioxidants may ameliorate CP-induced 
myelosuppression. Selenium (Se) is a nutrition-
ally essential trace element with anticarcinogenic 
properties. It is a constituent of several enzymes, 
such as glutathione peroxidase (GPx), phospholi-
pidhydroperoxide, and thioredoxin reductase, 
which remove hydroperoxides formed during oxi-
dative metabolism, thereby reducing the potential 
for  oxidative damage to DNA, proteins, and poly-
unsaturated membrane phospholipids (Nomura 
et al., 2000; Spallholz, 2003). Se nutritionally acts 
by its enzymes, cytosolic GPx or membrane-bound 
phospholipidhydroperoxide, and thioredoxin 
reductase, to control levels of cellular hydroper-
oxides and the redox tone of cells that can damage 
proteins, cell and organelle membranes, and DNA 
(Spallholz, 2003). Se deficiency has been found to 
reduce GPx activity in rats, having a glomerular 
disease and in tubular epithelium of the normal 
rats (Jamba et al., 1997). Limited data from studies 
in humans  suggest that Se supplementation may 
enhance immunity, including both humoral and 
cell-mediated responses (Hoffmann and Berry, 
2008). It was demonstrated that Se is a highly effec-
tive modulator of the  therapeutic efficacy and 
selectivity of anticancer drugs in nude mice bear-
ing human tumor xenografts of colon carcinoma 
and squamous-cell carcinoma of the head and 
neck. Thus, the use of Se as a selective modulator of 
the therapeutic efficacy of anticancer drugs is new 
and novel (Cao et al., 2004). Human Se-deficiency 
diseases, such as Keshan disease (a human heart 
disease) and Kashin-Beck disease (a human 
rheumatoid  condition), turned up in the 1980s in 
China and Russia. These and other diseases were 
all  prevented by the addition of relatively small 
amounts of Se salts to the diet (Spallholz, 2003). 
Based on these facts, the possible protective effect 
of Se on CP-induced toxicity of the blood and bone 
marrow of rats were investigated in this study.
Materials and Methods
A total of 84 Sprague-Dawley rats of either sex, 
weighing 190–220 g, were used for the i.p. injec-
tion of CP (Endoxan; Sigma-Aldrich, Taufkirchen, 
Germany; C0768) and SLM (seleno-L-methionine; 
Sigma; S3132). Animals were given food and water 
ad libitium. The rats were randomly divided into 
the following experimental groups, each including 
7 animals: Groups 1, 2, and 3 were treated with 50, 
100, or 150 mg/kg of CP, respectively; groups 4 and 5 
were treated with 0.4 and 0.8 mg/kg of SLM, respec-
tively; groups 6, 7, or 8 were treated with respective 
CP plus 0.4 mg/kg of SLM; groups 9, 10, or 11 were 
treated with respective CP plus 0.8 mg/kg of SLM; and 
group 12 (control) were treated with saline.
The experimental procedure was followed as pre-
viously reported (Ayhanci et al., 2008). The animals 
in the first three groups received only CP in saline 
and were killed 3 days after the CP injection. The 
fourth and fifth groups received 0.4 or 0.8 mg/kg of 
SLM for 6 days. For the groups having CP plus SLM, 
SLM administration was started 3 days earlier than 
the CP administration and continued to the end of 
the experiment (6 days). On day 4, the animals were 
weighed again, relative doses of CP were estimated, 
and CP plus SLM was administered together. On day 
7, blood samples were collected and bone marrow of 
animals were resected under anesthesia. The control 
group was injected with the same amount of saline 
and killed at day 7 with all the other mentioned 
groups.
Under the ether anesthesia, the blood samples 
were collected by cardiac puncture, and then the 
animals were killed at either days 4 or 7. Both femurs 
were dissected, and bone marrow was flushed with 
saline into a test tube. Homogenized bone marrow–
nucleated cells and blood cells were counted with a 
cell counter (Coulter).
The results were expressed as means ± standard 
error of the mean. Statistical analysis was performed 
by using one-way analysis of variance (ANOVA), 
 followed by Tukey’s multiple range test, and P < 0.05 
was accepted as a statistical significance. Triplicate 
samples from each animal were taken, and the results 
were expressed as a mean for each animal.
Results
The increase in the leukocyte and platelet numbers 
for the group that received 0.4 mg/kg of SLM were 
not  statistically significant (P > 0.05), whereas the 
increase in bone marrow–nucleated cell number was 
statistically significant (P < 0.01). In the 0.8-mg/kg 
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SLM group the increase in leukocyte number, 
 compared to the control group, was not statisti-
cally significant (P > 0.05), but the increase in 
the number of the thrombocyte (10%) and bone 
marrow– nucleated cells (25%) was highly significant 
(P < 0.001; Figure 1).
When used alone, doses of 50, 100, or 150 mg/kg of 
CP caused 78, 89, and 92% reduction in the number 
of leukocytes, respectively (P < 0.001). Administered 
together with respective doses of CP, 0.4 mg/kg of 
SLM reduced the number of leukocytes by 34, 55, 
and 89%, respectively (P < 0.01). A 57% significant 
recovery was obtained only in the 50 + 0.4 mg/kg 
group. Administered together with respective doses 
of CP, 0.8 mg/kg of SLM reduced the number of leu-
kocytes by 74, 87, and 91%, respectively (P < 0.001), 
whereas 0.8 mg/kg of SLM did not have a protective 
effect on CP toxicity of the leukocytes at these doses 
(Figure 2).
The number of platelets in rats treated only with 
50, 100, or 150 mg/kg of CP alone decreased by 22, 
33, or 52%, respectively (P < 0.001). Administered 
together with respective doses of CP, 0.4 mg/kg of 
SLM reduced the number of thrombocytes by 5, 22, 
and 49%, respectively (P < 0.05). An 83% significant 
 recovery was obtained only in the 50 + 0.4 mg/kg 
CP+SLM group. Compared to the 100-mg/kg 
CP group, the increase in platelet number of the 
100 + 0.4 mg/kg CP+SLM group was 33%, whereas 
the increase was 6% in the 150 + 0.4 mg/kg CP+SLM 
group. Administered together with respective doses of 
CP, 0.8 mg/kg of SLM reduced the number of throm-
bocytes by 22, 25, and 25%, respectively (P < 0.001), 
whereas 0.8 mg/kg of SLM was not effective in the 
prevention of thrombocytopenia caused by 50 mg/kg 
of CP, but it was highly effective in preventing that 
caused by 100 and 150 mg/kg of CP (25 and 52%, 
respectively; Figure 3).
The number of bone marrow–nucleated cells 
decreased by 72, 90, or 94% after the administra-
tion of 50, 100, or 150 mg/kg of CP (P < 0.001). When 
 compared with the respective three doses of CP, 
0.4 mg/kg of SLM caused about 52, 50, or 42% recov-
ery in the number of bone marrow–nucleated cells, 
respectively (P < 0.05). Administered together with 
respective doses of CP, 0.8 mg/kg of SLM reduced the 
number of bone marrow–nucleated cells by 56, 87, 
and 92%, respectively (P < 0.001; Figure 4).
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Figure 1. The number of peripheral leukocytes, thrombocytes, 
and bone marrow– nucleated cells with the presence of saline, 
0.4 mg/kg of SLM, and 0.8 mg/kg of SLM.
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Figure 2. The number of peripheral leukocytes with the pres-
ence of saline, respective doses of CP, or CP plus SLM.
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Figure 3. Blood thrombocyte number of the rats after treatment 
with saline, respective doses of CP, or CP plus SLM.
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Discussion
The chemotherapeutic usefulness of  alkylating 
agents are derived from their ability to form a variety 
of DNA adducts that sufficiently alter DNA structure 
or function or both so as to have a cytotoxic effect 
on the cells. Many of them undergo a very complex 
activation process before they can generate reactive 
intermediates. Initial activation reaction of CP carried 
out by the microsomal oxidation system in the liver 
produces 4-hydroxy CP, a cytotoxic metabolite, which 
diffuses from hepatocytes into plasma and is dis-
tributed throughout the body. Then, 4-hydroxy CP is 
further converted to other cytotoxic metabolites, such 
as acrolein and phosphoramide mustard (PAM). PAM 
is known to cause myelosuppression (Kumar and 
Kuttan, 2005; Liang et al., 2007). Myelosuppression is 
a major potential toxic and dose-limiting side effect 
of CP. CP causes cross-linking of DNA and inhibi-
tion of DNA synthesis by acting on both cyclic and 
intermitotic cells, resulting in general depletion of 
immune component cells (George et al., 2008). In this 
study, CP showed up to 92% toxicity on the circulating 
white blood cells (WBCs) of rats in a dose-dependent 
manner. Similarly, after the single dose of CP injec-
tion, leukocyte counts began to fall (Fraiser et al., 
1991; Langford, 1997; Bergsagel et al., 1968). Further, 
administration of a single dose of 40 mg/kg CP to 
baboons resulted in transient reduction in WBC count 
(Schuurman et al., 2005). In our study, when 0.4 mg/kg 
of SLM was used together with 50 mg/kg of CP, a 
total recovery of leukocytes was about 44%; however, 
when 0.8 mg/kg of SLM was administrated with the 
same dose of CP, a total recovery of leukocytes was 
about 4%. These results indicate that 0.8 mg/kg of 
SLM does not exhibit a high protection when used 
with CP. Compared to the control group, the increase 
in leukocyte and platelet numbers in the 0.4-mg/kg 
SLM group was not significant (P > 0.05), whereas the 
increase in the bone marrow–nucleated cell number 
was found to be significant (P < 0.01). Compared to the 
control group, the increase in leukocyte number was 
not found to be statistically significant in the 0.8-mg/
kg SLM group, whereas the increase in platelet (10%) 
and bone marrow–nucleated cell (25%) number 
was found to be highly significant. Neither 0.4 nor 
0.8 mg/kg of SLM protected the leukocytes from the 
toxic effect of 150 mg/kg of CP. The toxic effect of our 
doses of CP on the bone marrow–nucleated cell was 
similar to the effects on leukocytes, but 0.4 mg/kg of 
SLM appeared to be more effective on bone marrow. 
The best recovery, of about 52%, was obtained with 
0.4 mg/kg of SLM used together with 50 mg/kg of CP; 
but even with the highest (150 mg) CP dose, there was 
about 42% recovery of the bone marrow cells. Olas 
and Wachowicz (1997) reported that the administra-
tion of sodium selenite appears to reduce cisplatin 
toxicity without inhibiting the antitumor activity of 
cisplatin. Recently, Weijl et al. (2004) have found that 
supplementation with a higher dose of Se in combi-
nation with other  antioxidants (e.g., vitamins C and 
E) could correlate with cisplatin-induced ototoxicity 
and nephrotoxicity. Moreover, Se administration for 
3 months resulted in a significant increase of WBC 
(Sieja and Talerczyk, 2004). The deprivation of Se can 
reduce the protection against oxidative stress and 
impair immunocompetence, as certain cancer cells 
appear to have acquired a selective survival advantage 
that is apparent under conditions of Se deficiency and 
oxidative stress (Zeng and Combs, 2008).
The least toxic effect of CP was observed on the 
circulating thrombocytes, with 150 mg/kg CP causing 
only about 52% reduction in blood platelet count. A 
similar result was reported, indicating that reduction 
in platelets occurs only at high doses of CP (Bergsagel 
et al., 1968). There was a complete protection when 
we used 0.4 mg/kg of SLM with 50 mg/kg of CP. The 
number of platelets in rats treated with 50, 100, or 
150 mg/kg of CP decreased by 22, 33, and 52%, respec-
tively. Administered together with respective doses of 
CP, 0.4 mg/kg of SLM reduced the number of thrombo-
cytes by 5, 22, and 49%, respectively. About a 83% sig-
nificant recovery was obtained only in the 50 + 0.4 mg/
kg CP+SLM group. Compared to the 100-mg/kg CP 
group, the platelet number in the 100 + 0.4 mg/kg 
CP+SLM group increased by 33%, whereas the increase 
in platelet number in the 150 + 0.4 mg/kg CP+SLM 
group was estimated as 6%. Administered together 
with respective doses of CP, compared to the control, 
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Figure 4. The number of bone marrow–nucleated cells in the 
control, CP-, or CP plus SLM–treated groups.
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0.8 mg/kg of SLM reduced the number of thrombo-
cytes by 22, 25, and 25%, respectively, whereas 0.8 mg/
kg of SLM was not found to be effective in the preven-
tion of  thrombocytopenia caused by 50 mg/kg of CP, 
but it was found to be highly effective in the preven-
tion of thrombocytopenia caused by 100 and 150 mg/
kg of CP (25 and 52%, respectivly). Further studies are 
needed to substantiate the effect of Se on CP toxicity 
of the platelets.
Conclusions
In conclusion, Se alone is not toxic to bone marrow 
or blood cells, but CP is toxic to bone marrow, leu-
kocytes, and platelets. However, depending on the 
dose, Se protects the animals from the toxic effect of 
CP. The best recovery was obtained when 0.4 mg/kg 
of SLM was given in combination with 50 mg/kg 
of CP. Our findings suggest that at the appropriate 
 concentration, Se could be a potentially effective drug 
in the treatment of CP-induced damage and could be 
used in the prevention and treatment of CP toxicity. 
Additional experimentation should be performed to 
explore the underlying mechanism of selenium pro-
tection against CP toxicity.
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